Funded yes but not fully funded. My concern is that we are rudderless and possibly heading for the perfect storm. We only have enough capital to complete the current trial and progress our pre-clinical work. Even if the trial results are good, they are only Plla and not Plll and they are to be released into a mature HCV market at a time when there is (probably) still going to be a significant lull in biotech market sentiment. This means that the TT-034 results could be insufficient to arouse major interest in BLT. This could be the environment in which we need to raise more capital. A possible perfect storm. To counter this we need to start making changes sooner rather than later and for this we need a new CEO. Furthermore, the task oriented corporate culture that Peter fostered needs to be replaced with an outcome based corporate culture. We can no longer afford to fail to achieve our targets and the Board needs to stop being so slack as to allow this to continue, as they did for years under Peter’s tenure. These are significant changes and they need to start now if that storm does hit. I hope it does not, but we have to be prepared.
BLT Price at posting:
25.0¢ Sentiment: None Disclosure: Held